导管内前列腺癌在治疗前前列腺癌患者中经18F-DCFPyL-前列腺特异性膜抗原-正电子发射断层扫描/CT显示对淋巴结转移的倾向性
本研究为横断面分析,纳入2016年1月1日至2021年8月在玛格丽特公主癌症中心接受治疗前18F-DCFPyL-PSMA-PET/CT的120例前列腺癌患者,评估活检中导管内前列腺癌(IDC)与PSMA-PET/CT所示转移的关联。结果显示IDC与总体转移风险升高相关(OR 2.47,95%CI 1.09-5.61,P=0.03),且与淋巴结转移 vs 无转移风险升高相关(OR 3.03,95%CI 1.24-7.40,P=0.01)。作者认为IDC形态可能是18F-DCFPyL-PET/CT上淋巴结转移的标志物。
要点
- 120例治疗前前列腺癌患者中,55例(46%)活检存在IDC,48例(40%)存在筛状结构。
- 52例(43%)患者有转移证据,其中41例(79%)为淋巴转移。
- 活检IDC与总体转移风险升高相关(OR 2.47,95%CI 1.09-5.61,P=0.03)。
核心结论
- 在前列腺癌治疗前分期场景中,前列腺活检标本中发现IDC形态与18F-DCFPyL-PET/CT上的淋巴结转移显著相关。
- 前列腺活检中存在IDC似乎是18F-DCFPyL-PET/CT上淋巴结转移的标志物。
研究设计与样本
- 本研究为横断面分析,纳入2016年1月1日至2021年8月在玛格丽特公主癌症中心接受治疗前18F-DCFPyL-PSMA-PET/CT的所有前列腺癌患者。
- 队列共120例患者,IDC和筛状结构分别见于55例(46%)和48例(40%)前列腺活检。
- 采用单变量和多变量逻辑回归分析评估活检IDC与研究结局的关联。
主要发现
- 52例患者(43%)有转移证据。
- 52例有转移证据的患者中,41例(79%)有淋巴转移证据。
- 活检存在IDC与总体转移风险升高相关(OR 2.47,95%CI 1.09-5.61,P=0.03)。
- 活检存在IDC与淋巴转移 vs 无转移风险升高相关(OR 3.03,95%CI 1.24-7.40,P=0.01)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Intraductal prostate cancer (IDC) is linked to unfavorable oncologic outcomes, marked by distinctive cellular intrinsic pathway changes and intricate immunosuppressive microenvironments that could impact the way cancer spreads. The aim of this study was to determine whether the presence of IDC in prostate biopsy specimens obtained from patients before primary prostate cancer (PCa) treatment is associated with a lymph node metastatic propensity in prostate-specific membrane antigen (PSMA)‒positron emission tomography (PET)/CT. MATERIALS AND METHODS: This was a cross-sectional analysis of all PCa patients undergoing a pretreatment 18F-DCFPyL-PSMA-PET/CT between January 1, 2016, and August 2021 at The Princess Margaret Cancer Centre. Outcomes were presence of any metastasis in the overall cohort, presence of lymphatic vs no metastases, and presence of lymphatic vs bone metastasis among patients who underwent PSMA-PET/CT as PCa primary staging. The associations between IDC presence on the prostate biopsy and the study outcomes were evaluated using univariable and multivariable logistic regression analyses. RESULTS: The cohort consisted of 120 patients. IDC and cribriform pattern were observed in 55 (46%) and 48 (40%) prostate biopsies, respectively. Overall, 52 patients (43%) had evidence of metastasis. Presence of IDC on biopsy was associated with increased odds of overall metastasis (odds ratio: 2.47, 95% CI: 1.09-5.61, P = .03). Of the 52 patients with evidence of metastasis, 41 (79%) had evidence of lymphatic metastasis. Presence of IDC on biopsy was associated with significantly increased odds of lymphatic metastasis vs nonmetastases (odds ratio: 3.03, 95% CI: 1.24-7.40, P = .01). CONCLUSIONS: The identification of IDC morphology in prostate biopsy specimens has been observed to be significantly linked with lymph node metastasis on 18F-DCFPyL-PET/CT imaging in a PCa pretreatment staging setting. We found that presence of IDC in prostate biopsy appears to be a marker for lymph node metastasis on 18F-DCFPyL-PET/CT.
引用
- Bernardino R, Sayyid RK, Lajkosz K, et al. Intraductal Prostate Cancer Affinity for Lymphatic-Predominant Metastases Through 18F-DCFPyL‒Prostate-Specific Membrane Antigen‒Positron Emission Tomography/CT Scans in Pretreatment Prostate Cancer Patients. J Urol. 2024. PMID: 38299501. doi:10.1097/JU.0000000000003850
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。